---
title: "Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in HER2-Mutant NSCLC Acr"
id: "journal-of-thoracic-oncology-20-systemic-and-intracranial-efficacy-and-safety-of-trastuzumab-deruxtecan-in-patients-with-her2-mutant-non-small-cell-lung-cancer-across-treatment-lines-evidence-from-the-tracer-hertras-real-world-cohort"
canonical_url: "https://medichelpline.com/clinical-feed/journal-of-thoracic-oncology-20-systemic-and-intracranial-efficacy-and-safety-of-trastuzumab-deruxtecan-in-patients-with-her2-mutant-non-small-cell-lung-cancer-across-treatment-lines-evidence-from-the-tracer-hertras-real-world-cohort"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Journal of Thoracic Oncology (JTO)"
source_url: "https://www.jto.org/article/S1556-0864(26)00104-8/fulltext?rss=yes"
published_at: "2026-02-24T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in HER2-Mutant NSCLC Acr
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/journal-of-thoracic-oncology-20-systemic-and-intracranial-efficacy-and-safety-of-trastuzumab-deruxtecan-in-patients-with-her2-mutant-non-small-cell-lung-cancer-across-treatment-lines-evidence-from-the-tracer-hertras-real-world-cohort
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Journal of Thoracic Oncology (JTO)
- **Source URL:** [Original Journal Publication](https://www.jto.org/article/S1556-0864(26)00104-8/fulltext?rss=yes)
- **Published At:** 2026-02-24T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
HER2 mutations define a distinct, therapeutically actionable subset of non-small cell lung cancer (NSCLC). Trastuzumab deruxtecan (T-DXd) has demonstrated strong activity in clinical trials, but real-world data are limited.
## Clinical Analysis & Structured Key Points
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 24 Feb 2026. The item focuses on Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort. Review the original article for the full source wording and details.
## Related Clinical Research

- [Stepwise Molecular Profiling Reveals Co-occurring EGFR L858R and HER2 Amplification in NSCLC](https://medichelpline.com/clinical-feed/pubmed-42681853.md) (DOI: 10.12659/AJCR.953829)
- [Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial](https://medichelpline.com/clinical-feed/british-journal-of-cancer-1-maintenance-capecitabine-after-first-line-platinum-based-chemotherapy-in-advanced-oesophagogastric-adenocarcinoma-final-analysis-from-the-platform-trial.md)
- [Antibody-Drug Conjugate Candidates Show Promise for SCLC and Other Tumors](https://medichelpline.com/clinical-feed/pubmed-42249527.md) (DOI: 10.1158/2159-8290.CD-NW2026-0066)
- [VISTA: Virtual spatial transcriptomics from H&E for prognostic and therapy response prediction in](https://medichelpline.com/clinical-feed/biorxiv-21-virtual-spatial-transcriptomics-from-histopathology-enables-prognostic-and.md)
- [Next-generation Antibody–Drug Conjugates: Strategies to Improve Efficacy and Clinical Development](https://medichelpline.com/clinical-feed/nature-0-the-next-generation-of-antibody-drug-conjugates.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.